Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer

Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma

“…Several immunohistochemical studies have investigated the inactivation of p53. In some of these studies, a positive p53 IHC was associated with shortened survival (Starzynska et al, 1992;Auvinen et al, 1994), although the effect was weak or absent in others (Scott et al, 1991;Bell et al, 1993). We have previously reported a similar study in which we did not find an association between p53 IHC and survival (Mulder et al, 1995).…”

“…Because of the relative ease of this approach, a large number of studies have investigated alterations in p53 using immunohistochemistry (Campo et al, 1991;Cunningham et al, 1992;Kaklamanis et al, 1993;Auvinen et al, 1994;Scott et al, 1991;Starzynska et al, 1992;Bell et al, 1993). In some reports these findings were accompanied by a mutational a'nalysis of exons 5 -8 of the p53 gene (Cunningham et al, 1992;Cripps et al, 1994).…”

Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer

“…The result is thus in contrast to Houbiers et al (1995), who did not find an independent relation with prognosis in a multivariate analysis including the Dukes' stage but reported a weak association (P = 0.04) between high p53 serum levels and prognosis in patients with an early stage of the disease (Dukes' stage A). (Levine et al, 1991;Remvikos et al, 1992; Sun et al, 1992; Vogelstein and Kinzler, 1992;Bell et al, 1993;Auvinen et al, 1994;Bosari et al, 1994;Dix et al, 1994a;Hamelin et al, 1994;Goh et al, 1995). A mutation in the p53 gene results in an accumulation of mutant p53 protein or in an overproduction of normal wild-type p53 protein (Dix et al, 1994a and b).…”

“…Overexpression of the p53 protein is detectable in 30-70% of the tumours using immunohistochemistry. In some studies (Remvikos et al, 1992;Sun et al, 1992;Auvinen et al, 1994;Bosari et al, 1994) p53 protein overexpression has been shown to correlate to patient survival, while this has not been confirmed in other studies (Bell et al, 1993;Baas et al, 1994;Dix et al, 1994a;Morrin et al, 1994;Mulder et al, 1995;Kressner et al, 1996Poller et al, 1997).…”

“…Overexpression of the p53 protein is detectable in 30-70% of the tumours using immunohistochemistry. In some studies (Remvikos et al, 1992; Sun et al, 1992;Auvinen et al, 1994;Bosari et al, 1994) p53 protein overexpression has been shown to correlate to patient survival, while this has not been confirmed in other studies (Bell et al, 1993; Baas et al, 1994;Dix et al, 1994a;Morrin et al, 1994;Mulder et al, 1995;Kressner et al, 1996Poller et al, 1997).Mutant p53 protein, and other tumour-specific antigens, may be a target of the host's immune response (Schlichtholtz et al, 1992;Mudenda et al, 1994). Studies have shown that 9-26% of patients with different carcinomas have mounted a humoral immune response (antibodies) to abnormal p53 protein (Caron de Fromental et al, 1987;Levine et al, 1991;Angelopoulou et al, 1994).…”